Stay updated on Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.

Latest updates to the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAddition of Revision: v3.4.2 is shown on the page. The funding/status notices have been removed (including the lapse in government funding message and the earlier Revision: v3.4.1 reference).SummaryDifference0.2%

- Check20 days agoChange DetectedA site-wide notice regarding a lapse in government funding is displayed, stating information may not be up to date and transactions may not be processed. The page also shows a revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check28 days agoChange DetectedEditorial/metadata updates include showing the glossary, updating the QC criteria label, capitalization tweaks for FEAR Act data, and a new revision tag (v3.4.0), and these changes do not affect the core study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4, a minor metadata/UI change. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThe Study Locations section was updated with many new sites across the US, Canada, Argentina, France, Germany, Japan, Spain, and the UK, and several existing sites were removed. This expands and refines the recruitment footprint across multiple countries.SummaryDifference2%

- Check78 days agoChange DetectedA new PubMed citation has been added to the Publications section: 'Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naive Patients with Chronic Spontaneous Urticaria' (Dermatol Ther (Heidelb), online ahead of print, 2025 Dec 2, doi:10.1007/s13555-025-01605-w). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.